09Oct

BBI Solutions adds more antibodies to product range

BBI Solutions has continued to invest in its portfolio of antibodies and today announced the launch of 10 infectious disease markers, 3 inflammatory markers, 2 fertility markers and an additional cardiac marker. All the antibodies have been tested in either lateral flow or ELISA and are available for sampling today.

BBI Solutions (BBI) is in a rapid period of expansion and growth with recent announcements of a £14m investment into a global headquarters for the BBI Group and a recent acquisition of Maine Biotechnology Services. This further investment in to the expansion of BBI’s antibodies portfolio forms another part of the company’s growth plans as they continually aim to meet the growing demands of their customers.

BBI’s new infectious disease markers include H. pylori, Influenza A and B, E. coli O157, Campylobacter and Legionella pneumophila. BBI have also released antibodies for three inflammatory markers; Calprotectin, CRP and IL-6, two fertility markers; AMH and Estriol and Myoglobin antibodies as a cardiac marker.

James Steggles, BBI’s Antibodies Commercial Manager explained “we are pleased to be able to offer this range of high quality antibodies that test developers can use with confidence as part of their research and development assay programs. As they aim to improve diagnosis of key diseases and conditions.”

BBI’s mission is to deliver exceptional products and technologies that people rely on to enjoy a better quality of life. “We have selected these antibodies following requests from our customers. They also work towards achieving our mission and our growth plans”, continued James.

All of BBI’s new antibodies have either been tested in lateral flow or ELISA assays, many are already being used in commercial assays and there are a number of recommended matched pairs, which will save time and money in customer’s screening processes. To discover more about these antibodies and their matched pairs or to order a sample visit our website or call today www.bbisolutions.com +44 (0) 2920 747 232.

About

BBI Solutions is a leading manufacturer of raw materials and finished test platforms for the in-vitro diagnostics market. BBI has grown from a small specialist company to a global business with manufacturing sites spanning three countries.

Our range of raw materials includes human antigens, antibodies, serum and plasma products and clinical chemistry enzymes. We manufacture world renowned labels for lateral flow, ELISA assay and biosensors, including our gold nanoparticles and glucose oxidase.

BBI Solutions offer contract development and manufacturing services with a core focus on gold conjugation and lateral flow test manufacture.

BBI Solutions is part of the BBI Group.

www.bbisolutions.com

Related

Reduce Your Costs for Biological Sample Transport

How do you package your send-away pathology samples? Are you spending too much time and money on pac...

Read More >

Mologic receives a $4.8m grant to establish the centre for advanced rapid diagnostics ("card")

Mologic is pleased to announce that we are in receipt of a grant from the Bill & Melinda Gates Found...

Read More >

FDA grants de novo designation for OGT’s AML/MDS FISH probes

Clearance enables accurate and easy-to-interpret AML and MDS detection with reduced validation burde...

Read More >

DEMAND FOR GENETIC TESTING DRIVES GROWTH FOR AWARD WINNING ELUCIGENE DIAGNOSTICS

30 percent growth and innovation products wins Manchester company BVCA award. Having the right te...

Read More >

Cytox in Collaboration with AKESOgen Extends Genetic Test for Assessing Alzheimer's Disease

8th May 2018: Oxford & Manchester, UK and Atlanta, GA. Cytox, a precision medicine testing company ...

Read More >

EKF to highlight Lucica® Glycated Albumin-L assay for diabetes patient monitoring at AACC 2019

Specific, intermediate glycemic control marker for diabetes at EKF’s Booth #2952 at AACC 2019 Clini...

Read More >